Related Experiment Video
Updated: May 9, 2026
03:57
Electrochemotherapy of Tumours
Published on: December 15, 2008
[Intravesical therapy with mitomycin through electromotive drug administration]
Cristian Verri1, Emanuele Liberati, Francesco Celestino
1Unità Operative Semplice de Urologia Oncologia, Policlinico Casilino, Roma, Italy.
Urologia
|July 16, 2013
Summary
Electromotive drug administration (EMDA) enhances mitomycin-C (MMC) delivery for non-muscle invasive bladder cancer (NMIBC). This novel approach improves treatment efficacy and remission rates, offering a potential breakthrough in urothelial cancer management.
Area of Science:
- Uro-oncology
- Pharmacology
- Biomedical Engineering
Context:
- Non-muscle invasive bladder cancer (NMIBC) management relies on intravesical mitomycin-C (MMC).
- Standard transurethral resection of bladder tumor (TURBT) alone has limited long-term efficacy.
- Intravesical therapies aim to improve treatment outcomes for NMIBC.
Purpose:
- To evaluate the efficacy of electromotive drug administration (EMDA) for enhancing intravesical MMC delivery in NMIBC.
- To explore novel treatment frameworks utilizing EMDA/MMC for improved NMIBC management.
- To assess the potential of EMDA-enhanced MMC as a therapeutic breakthrough.
Summary:
- EMDA controls and enhances MMC tissue transport, increasing bladder uptake.
- Clinical studies show EMDA/MMC improves NMIBC efficacy without systemic side effects.
- New treatment protocols combining EMDA/MMC with BCG or preceding TURBT show promising results.
Impact:
- EMDA-enhanced MMC offers improved clinical efficacy and higher remission rates for NMIBC.
- This approach may reduce recurrence and progression, impacting long-term outcomes.
- EMDA/MMC presents a significant advancement in treating urothelial cancer, potentially lowering disease management costs.